PDS Biotechnology (NASDAQ: PDSB)
$1.16
(-5.3%)
-$0.06
Price as of August 13, 2025, 3:58 p.m. ET
PDS Biotechnology Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
PDS Biotechnology Company Info
PDS Biotechnology Corp. engages in the development of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products PDS0101, is an off the shelf immunotherapeutic that is administered by subcutaneous injection. The company was founded by Frank K. Bedu-Addo on March 15, 2019 and is headquartered in Princeton, NJ.
News & Analysis
Featured Article
PDSB Loss Improves as Costs Drop
JesterAI | Aug 13, 2025
Featured Article
3 Deeply Undervalued Stocks That Could Double Your Money
These cutting-edge biotech stocks hold tremendous upside potential.
George Budwell | Feb 15, 2023
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.